Worldwide Healthcare News

Europe would continue to dominate the market while Asia Pacific would emerge as fastest growing region over the forecast period.   biosimilars market   was valued at $2,552.0 million in 2014 and is expected to reach $26,551.3 million by 2020, supported by a CAGR of 49.1% during the forecast period 2015 to 2020.  Glycosylated proteins namely, erythropoietin and monoclonal antibodies are the leading biosimilar segments commercially available across the globe, together accounting for about one-third of the market revenue in 2014. This significant hold in the market is chiefly due to its large application in the treatment of chronic conditions such as blood related disorders, cancer, among others. Key findings of the study:   The biosimilar applications in blood disorders and oncology collectively evaluated at 61% in 2014 Interferon is fastest growing biosimilar, expected to grow at a CAGR of 51.1% during the forecast period U.S. would find space in biosim...

Global Biosimilars Market  (Follow-on-Biologics) by Types (Human growth hormone, Erythropoietin, Monoclonal antibodies, Insulin, Interferon, Granulocyte-Colony Stimulating Factor, Peptide), Application (Blood disorders, Oncology diseases, Growth hormone deficiencies) is projected to grow at a CAGR of 49.1% from 2015 to 2020, according to new research published by Allied Market Research. Download the Sample Report @  http://bit.ly/2KQLrPb Europe would continue to dominate the market while Asia Pacific would emerge as fastest growing region over the forecast period. Recent approval of Zarxio (filgrastim-sndz) as first biosimilar by U.S. FDA has opened new opportunities for biosimilar manufactures. Patents for number of blockbuster bio-pharmaceuticals have either expired or are on the verge of expiration, which is majorly driving the growth of biosimilars industry. Changes in regulatory guidelines and convenient biosimilar drug approval processes have a major impact on th...